The Fukushima disaster has prompted calls to review legislation passed by the Indian parliament in August 2010 that capped compensation payable, in the event of a nuclear accident, at 320 million U.S. dollars. "Fukushima showed what the potential damage from an accident could be," M.V. Ramana, physicist and well-known commentator on nuclear energy safety issues, told IPS. "The economic damages [at Fukushima] must have certainly exceeded the compensation allowed in the nuclear...

Anti-nuclear campaigners in India see the earthquake that hit Japan last week, which threatens the meltdown of the Fukushima atomic power facility there, as a wakeup call for this country’s ambitious nuclear power programme. When India completed a nuclear power cooperation deal with the United States in October 2008, it threw open a 270 billion U.S. dollar market for nuclear reactors. Now members of the 45-nation Nuclear Suppliers’ Group are queuing...

The new bribery revelations, a rigged process to import reactors and safety-related concerns must lead to the long-blocked scrutiny of the nuclear deal by Parliament. The world's worst nuclear accident since Chernobyl raises troubling questions about India's plans for a huge expansion of its nuclear power programme through reactor imports. Given its low per-capita energy consumption, India must generate far more electricity to economically advance. So it needs more nuclear-generated power....

Going with its slogan: “Our money our right,” the Shillong declaration of the 3rd National Right to Information Convention today resolved that the Central Government must subject “all public expenditure under social audit.” It was by far one of the most crucial of the other 11 resolutions passed in the Shillong Declaration and was only included after the strong insistence of RTI activist, Aruna Roy. She was amply supported by some...

India’s drug regulator has refused to disclose key information about a controversial government study that provided Indian girls a vaccine designed to protect them from cervical cancer, amplifying suspicions about the study’s objectives. The Drug Controller General of India (DCGI) has refused to release for public scrutiny the study’s protocols, which are expected to contain information about its purpose and methodology, a set of health activists said yesterday. The Union government had...